LLY Lilly (Eli)

XNYS Up Alert

Health Care

· How we analyze

About the company

Eli Lilly is a US pharmaceutical company. Its drugs for diabetes and obesity such as Mounjaro and Zepbound are in particularly high demand. Other focus areas are cancer, immune diseases and Alzheimer’s; it sells worldwide. As of Oct 11, 2026

Fact sheet (from the annual report) Pharmaceutical manufacturers · Indianapolis, USA

The company researches, develops, manufactures and markets human pharmaceuticals in a single business segment. Manufacturing and distribution run through sites in the United States including Puerto Rico as well as in Europe and Asia. In cardiometabolic health, the group offers insulins, Mounjaro for a certain form of diabetes and a medicine for obesity or overweight with a comorbidity. It markets some diabetes medicines in collaboration with Boehringer Ingelheim. Oncology includes Verzenio and Inluriyo for certain forms of breast cancer, among others. Other therapeutic areas are immunology and neuroscience.

Automatically summarized from SEC annual report (10-K, filed Feb 12, 2026) (website of the US Securities and Exchange Commission) · reviewed Oct 14, 2026

Price performance at a glance

Last 30 trading days
  • Today +0.2%
  • 7 days −0.1%
  • 30 days +8.3%
  • 1 year +55.1%
Day range (last trading day)
−0.8%Price at 38% of the range+1.2%
52-week range
−36.8%Price at 92% of the range+3.1%
Distance from the all-time high
−3.0%

Our own calculation from the exchange’s daily candles, as of Oct 27, 2026. “All-time” applies since the start of this series, not to the whole market. Changes in percent; the TradingView chart shows prices. “Today” = change of the last trading day versus the previous day. Not investment advice.

Gap with volume · Analysis method

This method currently detects no pattern for LLY. The check runs daily after the close.

You see new patterns immediately from Watcher, on the free plan 2 days after they form. Plans and pricing

What does the pattern show?

What is this? After strong news, usually earnings, the price opened above the previous day’s high and closed much higher on heavy volume. Such moves often continue for a few more days.

This is a calculated analysis, not a forecast and not a call to buy. Risk notice and investment advice

Load chart from TradingView

This transfers data (including your IP address) to TradingView, also to the USA. More in the Privacy policy.

Symbol on TradingView: NYSE:LLY

Fundamental analysis

Lilly (Eli) · Sector Health Care · amounts in USD

Information only – does not affect the other analysis methods, not investment advice. Source: SEC filings, As of Feb 12, 2026.

Quality checks

Four angles on the annual figures. Each check counts how many disclosed criteria are met – criteria without data do not count. The bars show where the company ranks on each figure among the stocks we cover and within its sector.

Fiscal year to Dec 31, 2025

Quality Profitability, consistency, balance sheet · 1 without data 6 of 7 criteria met Growth Revenue and earnings per share 7 of 7 criteria met Dividend Level, consistency, coverage 7 of 7 criteria met Financial strength Piotroski, debt, liquidity 5 of 6 criteria met

Quality 6 of 7 met · 1 without data

  • met: Gross margin above 40% 83.0%
  • no data: Operating margin above 15% not stated in the SEC filings
  • met: Net margin above 10% 31.7%
  • met: Return on equity above 15% 77.8%
  • met: Free cash flow margin above 10% 13.8%
  • met: Profit in each of the last 5 fiscal years 5 of 5
  • met: Free cash flow positive in each of the last 3 fiscal years 3 of 3
  • not met: Equity ratio above 30% 23.6%
Gross margin

83.0% Fiscal year 2025

Rank 96 of 100: higher than 96% of 153 peers (All). strong.

Rank 88 of 100: higher than 88% of 20 peers (Sector). strong.

Median Health Care: 66.6%

Share of revenue left after the direct cost of the products sold.

Net margin

31.7% Fiscal year 2025

Rank 88 of 100: higher than 88% of 237 peers (All). strong.

Rank 90 of 100: higher than 90% of 26 peers (Sector). strong.

Median Health Care: 13.9%

Profit after all costs, interest and taxes divided by revenue.

Return on equity

77.8% Fiscal year 2025

Rank 95 of 100: higher than 95% of 218 peers (All). strong.

Rank 93 of 100: higher than 93% of 21 peers (Sector). strong.

Median Health Care: 14.3%

Net income divided by equity at fiscal year end.

Return on assets

18.4% Fiscal year 2025 (total assets at year end)

Rank 90 of 100: higher than 90% of 238 peers (All). strong.

Rank 94 of 100: higher than 94% of 26 peers (Sector). strong.

Median Health Care: 6.4%

Net income divided by total assets at fiscal year end.

Equity ratio

23.6% Fiscal year 2025

Rank 32 of 100: higher than 32% of 239 peers (All). weak.

Rank 29 of 100: higher than 29% of 26 peers (Sector). weak.

Median Health Care: 38.5%

Equity as a share of total assets. Usually low for banks.

Free cash flow margin

13.8% Fiscal year 2025

Rank 49 of 100: higher than 49% of 213 peers (All). medium.

Rank 38 of 100: higher than 38% of 25 peers (Sector). medium.

Median Health Care: 14.9%

Free cash flow divided by revenue.

Free cash flow

9.0B USD Fiscal year 2025

Operating cash flow minus capital expenditure on property and equipment.

Growth 7 of 7 met

  • met: Over 3 years, revenue grew by more than 5% per year +31.7%
  • met: Over 5 years, revenue grew by more than 5% per year +21.6%
  • met: Over 10 years, revenue grew by more than 5% per year +12.6%
  • met: Over 3 years, EPS grew by more than 5% per year +49.3%
  • met: Over 5 years, EPS grew by more than 5% per year +27.6%
  • met: Revenue rose in at least 4 of the last 5 fiscal years 5 of 5
  • met: Revenue rose in the last fiscal year +44.7%
Revenue growth 3 years

+31.7% per year

Rank 87 of 100: higher than 87% of 230 peers (All). strong.

Rank 94 of 100: higher than 94% of 25 peers (Sector). strong.

Median Health Care: +5.6%

Average growth per year over 3 fiscal years.

Revenue growth 5 years

+21.6% per year

Rank 76 of 100: higher than 76% of 217 peers (All). strong.

Rank 94 of 100: higher than 94% of 25 peers (Sector). strong.

Median Health Care: +8.5%

Average growth per year over 5 fiscal years.

Revenue growth 10 years

+12.6% per year

Rank 75 of 100: higher than 75% of 157 peers (All). strong.

Rank 71 of 100: higher than 71% of 19 peers (Sector). strong.

Median Health Care: +10.1%

Average growth per year over 10 fiscal years.

EPS growth 3 years

+49.3% per year

Rank 92 of 100: higher than 92% of 157 peers (All). strong.

Rank 98 of 100: higher than 98% of 22 peers (Sector). strong.

Median Health Care: +5.5%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 5 years

+27.6% per year

Rank 78 of 100: higher than 78% of 146 peers (All). strong.

Rank 93 of 100: higher than 93% of 20 peers (Sector). strong.

Median Health Care: +7.0%

Growth of earnings per share per year, adjusted for stock splits.

EPS growth 10 years

+26.1% per year

Rank 90 of 100: higher than 90% of 140 peers (All). strong.

Rank 98 of 100: higher than 98% of 20 peers (Sector). strong.

Median Health Care: +8.3%

Growth of earnings per share per year, adjusted for stock splits.

Dividend 7 of 7 met

  • met: Pays a dividend 6.23 USD
  • met: Payout ratio at most 60% of earnings 27%
  • met: Dividend paid in each of the last 5 fiscal years 5 of 5
  • met: Dividend per share never lowered in the last 5 fiscal years Dividend per share as filed with the SEC, including special dividends; a one-off higher prior year does not count as a cut. never
  • met: Dividend per share higher than 5 years ago +15.2%
  • met: Free cash flow per share covers the dividend 1.6x
  • met: Dividends paid over the last 5 years covered by free cash flow 84% of free cash flow
Payout ratio

27% Fiscal year 2025

Dividend per share divided by earnings per share.

Dividend growth 5 years

+15.2% per year

Rank 79 of 100: higher than 79% of 118 peers (All). strong.

Rank 84 of 100: higher than 84% of 16 peers (Sector). strong.

Median Health Care: +7.8%

Growth of the dividend per share per year.

Free cash flow coverage

1.6x Fiscal year 2025

Free cash flow per share divided by dividend per share. From 1x the dividend is covered.

Financial strength 5 of 6 met

  • met: Piotroski F-Score at least 7 of 9 7 of 9
  • not met: Long-term debt no higher than equity 1.54
  • met: Current assets cover current liabilities 1.58
  • met: Positive equity 26.5B USD
  • met: In 5 years, share count up by at most 5% −1.4%
  • met: Free cash flow positive in the last fiscal year 9.0B USD
Piotroski F-Score

7 of 9 Fiscal year 2025

Rank 72 of 100: higher than 72% of 134 peers (All). strong.

Rank 63 of 100: higher than 63% of 19 peers (Sector). medium.

Median Health Care: 7.0 of 9

Nine yes/no tests on profit, cash flow, debt, liquidity and efficiency compared with the prior year.

Debt / equity

1.54 at fiscal year end

Rank 20 of 100: lower than 20% of 199 peers (All). weak.

Rank 14 of 100: lower than 14% of 18 peers (Sector). weak.

Median Health Care: 0.72

Long-term financial debt divided by equity.

Liquidity (current ratio)

1.58 at fiscal year end

Rank 57 of 100: higher than 57% of 215 peers (All). medium.

Rank 56 of 100: higher than 56% of 26 peers (Sector). medium.

Median Health Care: 1.56

Current assets divided by current liabilities.

Change in share count

−1.4% in 5 years

Rank 49 of 100: lower than 49% of 199 peers (All). medium.

Rank 40 of 100: lower than 40% of 24 peers (Sector). medium.

Median Health Care: −2.7%

Change in diluted share count. Negative = share buybacks, positive = new shares.

The 9 criteria of the Piotroski F-Score
  • met: Profit in the last fiscal year (positive return on assets)
  • met: Positive operating cash flow
  • met: Return on assets higher than the prior year
  • not met: Operating cash flow higher than net income
  • not met: Long-term debt relative to total assets fell
  • met: Liquidity (current assets / current liabilities) rose
  • met: No additional shares (diluted share count did not rise)
  • met: Gross margin higher than the prior year
  • met: Revenue relative to total assets higher than the prior year

Last fiscal year compared with the one before. Returns and revenue per total assets use total assets at the start of the year; leverage = long-term financial debt divided by total assets at year end; new shares via the average diluted share count.

Price-based criteria (P/E, dividend yield) are shown to signed-in users.

Computed automatically from SEC annual reports – not investment advice. Describes the reported figures; points are not a rating of the stock. Rank 0–100 against the 239 stocks we cover and against the sector (from 5 peers); the stronger side is always on the right.

In short

  • Light green: Revenue grew over 5 years (+21.6% per year), at least as fast as the sector median.
  • Light green: Net income (total) grew over 5 years (+27.2% per year), at least as fast as the sector median; per share +27.6% per year.
  • Light green: Net margin 31.7%, above the sector median (12.9%).
  • Light red: Debt much higher than usual in the sector.
  • Light yellow: Profit in 9 of 10 fiscal years.

Summarized from the lights below. Describes the reported figures – not a recommendation to buy or sell.

RevenueNet income Net margin (below) in USD
  1. Fiscal year 2016 (Jan 1, 2016 – Dec 31, 2016): Revenue 21.2B USD · Net income 2.7B USD · Net margin 12.9%
  2. Fiscal year 2017 (Jan 1, 2017 – Dec 31, 2017): Revenue 22.9B USD · Net income −204.1M USD · Net margin −0.9%
  3. Fiscal year 2018 (Jan 1, 2018 – Dec 31, 2018): Revenue 24.6B USD · Net income 3.2B USD · Net margin 13.2%
  4. Fiscal year 2019 (Jan 1, 2019 – Dec 31, 2019): Revenue 22.3B USD · Net income 8.3B USD · Net margin 37.3%
  5. Fiscal year 2020 (Jan 1, 2020 – Dec 31, 2020): Revenue 24.5B USD · Net income 6.2B USD · Net margin 25.2%
  6. Fiscal year 2021 (Jan 1, 2021 – Dec 31, 2021): Revenue 28.3B USD · Net income 5.6B USD · Net margin 19.7%
  7. Fiscal year 2022 (Jan 1, 2022 – Dec 31, 2022): Revenue 28.5B USD · Net income 6.2B USD · Net margin 21.9%
  8. Fiscal year 2023 (Jan 1, 2023 – Dec 31, 2023): Revenue 34.1B USD · Net income 5.2B USD · Net margin 15.4%
  9. Fiscal year 2024 (Jan 1, 2024 – Dec 31, 2024): Revenue 45.0B USD · Net income 10.6B USD · Net margin 23.5%
  10. Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.2B USD · Net income 20.6B USD · Net margin 31.7%

Fiscal year 2025 (Jan 1, 2025 – Dec 31, 2025): Revenue 65.2B USD · Net income 20.6B USD · Net margin 31.7%

Figures over time

Where the money of a fiscal year goes and how margins, returns, balance sheet, cash flow and share count developed over up to 10 years. Each chart has one sentence saying what the trend shows.

Money flow in fiscal year 2025

Of 100 USD of revenue, 83.0 USD gross profit and 31.7 USD net income remained.

Money flow as a table
Fiscal year 2025, amounts in USD, share of revenue
ItemAmountof revenue
Revenue65.2B USD100.0%
Gross profit54.1B USD83.0%
Cost of revenue11.1B USD17.0%
Net income20.6B USD31.7%
Research & development13.3B USD20.5%
Interest expense895.0M USD1.4%
Taxes5.1B USD7.8%
Remaining costs & other14.2B USD21.7%

Taxes, interest and other items are not available separately in the SEC data; they are combined as the difference.

Margins

The net margin rose in 5 years from 25.2% to 31.7%.

Gross marginNet margin
  1. Fiscal year 2016: Gross margin 73.1% · Net margin 12.9%
  2. Fiscal year 2017: Gross margin 73.1% · Net margin −0.9%
  3. Fiscal year 2018: Gross margin 73.8% · Net margin 13.2%
  4. Fiscal year 2019: Gross margin 78.8% · Net margin 37.3%
  5. Fiscal year 2020: Gross margin 77.7% · Net margin 25.2%
  6. Fiscal year 2021: Gross margin 74.2% · Net margin 19.7%
  7. Fiscal year 2022: Gross margin 76.8% · Net margin 21.9%
  8. Fiscal year 2023: Gross margin 79.2% · Net margin 15.4%
  9. Fiscal year 2024: Gross margin 81.3% · Net margin 23.5%
  10. Fiscal year 2025: Gross margin 83.0% · Net margin 31.7%

Returns

Return on equity fell in 5 years from 109.8% to 77.8%.

Return on equityReturn on assets
  1. Fiscal year 2016: Return on equity 19.5% · Return on assets 7.1%
  2. Fiscal year 2017: Return on equity −1.8% · Return on assets −0.5%
  3. Fiscal year 2018: Return on equity 32.9% · Return on assets 7.4%
  4. Fiscal year 2019: Return on equity 319.1% · Return on assets 21.2%
  5. Fiscal year 2020: Return on equity 109.8% · Return on assets 13.3%
  6. Fiscal year 2021: Return on equity 62.2% · Return on assets 11.4%
  7. Fiscal year 2022: Return on equity 58.6% · Return on assets 12.6%
  8. Fiscal year 2023: Return on equity 48.6% · Return on assets 8.2%
  9. Fiscal year 2024: Return on equity 74.6% · Return on assets 13.5%
  10. Fiscal year 2025: Return on equity 77.8% · Return on assets 18.4%

Equity and long-term debt

The equity ratio rose in 5 years from 12.1% to 23.6%.

EquityLong-term debt in USD Long-term debt, depending on the filing, includes the current portion or leases.
  1. Fiscal year 2016: Equity 14.0B USD · Long-term debt 8.4B USD
  2. Fiscal year 2017: Equity 11.6B USD · Long-term debt 9.9B USD
  3. Fiscal year 2018: Equity 9.8B USD · Long-term debt 11.6B USD
  4. Fiscal year 2019: Equity 2.6B USD · Long-term debt 13.8B USD
  5. Fiscal year 2020: Equity 5.6B USD · Long-term debt 16.6B USD
  6. Fiscal year 2021: Equity 9.0B USD · Long-term debt 15.3B USD
  7. Fiscal year 2022: Equity 10.6B USD · Long-term debt 14.7B USD
  8. Fiscal year 2023: Equity 10.8B USD · Long-term debt 18.3B USD
  9. Fiscal year 2024: Equity 14.2B USD · Long-term debt 28.5B USD
  10. Fiscal year 2025: Equity 26.5B USD · Long-term debt 40.9B USD

Liquidity (current ratio)

The current ratio rose in 5 years from 1.40 to 1.58.

Current ratio
  1. Fiscal year 2016: Current ratio 1.37
  2. Fiscal year 2017: Current ratio 1.32
  3. Fiscal year 2018: Current ratio 1.73
  4. Fiscal year 2019: Current ratio 1.16
  5. Fiscal year 2020: Current ratio 1.40
  6. Fiscal year 2021: Current ratio 1.23
  7. Fiscal year 2022: Current ratio 1.05
  8. Fiscal year 2023: Current ratio 0.94
  9. Fiscal year 2024: Current ratio 1.15
  10. Fiscal year 2025: Current ratio 1.58

Cash flow

Free cash flow rose in 5 years from 5.1B USD to 9.0B USD.

Operating cash flowCapital expenditureFree cash flow in USD
  1. Fiscal year 2016: Operating cash flow 4.9B USD · Capital expenditure 1.0B USD · Free cash flow 3.8B USD
  2. Fiscal year 2017: Operating cash flow 5.6B USD · Capital expenditure 1.1B USD · Free cash flow 4.5B USD
  3. Fiscal year 2018: Operating cash flow 5.5B USD · Capital expenditure 1.2B USD · Free cash flow 4.3B USD
  4. Fiscal year 2019: Operating cash flow 4.8B USD · Capital expenditure 1.0B USD · Free cash flow 3.8B USD
  5. Fiscal year 2020: Operating cash flow 6.5B USD · Capital expenditure 1.4B USD · Free cash flow 5.1B USD
  6. Fiscal year 2021: Operating cash flow 7.3B USD · Capital expenditure 1.3B USD · Free cash flow 6.0B USD
  7. Fiscal year 2022: Operating cash flow 7.1B USD · Capital expenditure 1.9B USD · Free cash flow 5.2B USD
  8. Fiscal year 2023: Operating cash flow 4.2B USD · Capital expenditure 3.4B USD · Free cash flow 792.5M USD
  9. Fiscal year 2024: Operating cash flow 8.8B USD · Capital expenditure 5.1B USD · Free cash flow 3.8B USD
  10. Fiscal year 2025: Operating cash flow 16.8B USD · Capital expenditure 7.8B USD · Free cash flow 9.0B USD

Share count

The share count fell in 5 years by 1.4% (mostly through share repurchases).

Diluted share count
  1. Fiscal year 2016: Diluted share count 1.1B
  2. Fiscal year 2017: Diluted share count 1.1B
  3. Fiscal year 2018: Diluted share count 1.0B
  4. Fiscal year 2019: Diluted share count 935.7M
  5. Fiscal year 2020: Diluted share count 912.5M
  6. Fiscal year 2021: Diluted share count 911.7M
  7. Fiscal year 2022: Diluted share count 904.6M
  8. Fiscal year 2023: Diluted share count 903.3M
  9. Fiscal year 2024: Diluted share count 904.1M
  10. Fiscal year 2025: Diluted share count 899.3M

From annual reports filed with the SEC (10-K, 20-F, 40-F) as first reported, share count adjusted for splits; obvious filing errors (e.g. wrong unit, outliers against both neighbouring years) are hidden. Describes the reported figures – not investment advice.

Dividends and share repurchases

How much the company returns to its shareholders – as dividends or by repurchasing its own shares – and whether free cash flow supports it.

Dividend per share
6.23 USD · Fiscal year 2025
Dividend growth per year
3 y +15.2%5 y +15.2%10 y –
Years without a cut
at least 7 as far as the data goes
Payout ratio
of earnings 27% of free cash flow 60%
To shareholders (5 years)
30.9B USD 33% through repurchases
Share count over 5 years
−1.4% fewer shares – each share is a larger stake

Dividend per share

The dividend per share rose in 5 years from 3.07 USD to 6.23 USD.

Dividend per share USD per share Per share as filed with the SEC, including special dividends; obvious filing errors are hidden.
  1. Fiscal year 2016: Dividend per share 2.05 USD
  2. Fiscal year 2017: Dividend per share not available
  3. Fiscal year 2018: Dividend per share 2.33 USD
  4. Fiscal year 2019: Dividend per share 2.68 USD
  5. Fiscal year 2020: Dividend per share 3.07 USD
  6. Fiscal year 2021: Dividend per share 3.53 USD
  7. Fiscal year 2022: Dividend per share 4.07 USD
  8. Fiscal year 2023: Dividend per share 4.69 USD
  9. Fiscal year 2024: Dividend per share 5.40 USD
  10. Fiscal year 2025: Dividend per share 6.23 USD

Payout ratios

The payout ratio fell in 5 years from 45.2% to 27.1%.

Payout ratio (earnings)Payout ratio (free cash flow) Ratios above 500% hidden (earnings or free cash flow close to zero).
  1. Fiscal year 2016: Payout ratio (earnings) 79.5% · Payout ratio (free cash flow) 56.6%
  2. Fiscal year 2017: Payout ratio (earnings) not available · Payout ratio (free cash flow) 48.3%
  3. Fiscal year 2018: Payout ratio (earnings) 74.4% · Payout ratio (free cash flow) 53.6%
  4. Fiscal year 2019: Payout ratio (earnings) 30.1% · Payout ratio (free cash flow) 63.4%
  5. Fiscal year 2020: Payout ratio (earnings) 45.2% · Payout ratio (free cash flow) 52.6%
  6. Fiscal year 2021: Payout ratio (earnings) 57.7% · Payout ratio (free cash flow) 51.9%
  7. Fiscal year 2022: Payout ratio (earnings) 59.0% · Payout ratio (free cash flow) 67.6%
  8. Fiscal year 2023: Payout ratio (earnings) 80.9% · Payout ratio (free cash flow) not available
  9. Fiscal year 2024: Payout ratio (earnings) 46.1% · Payout ratio (free cash flow) 124.5%
  10. Fiscal year 2025: Payout ratio (earnings) 27.1% · Payout ratio (free cash flow) 60.0%

What goes back to shareholders

Over 5 years, 30.9B USD went back to shareholders, 33% of it through share repurchases. That is 125% of the free cash flow of those years.

Dividends paidShare repurchasesNew shares issued (including employee plans)Free cash flow in USD
  1. Fiscal year 2016: Dividends paid 2.2B USD · Share repurchases 600.1M USD · New shares issued (including employee plans) not available · Free cash flow 3.8B USD
  2. Fiscal year 2017: Dividends paid 2.2B USD · Share repurchases 299.8M USD · New shares issued (including employee plans) not available · Free cash flow 4.5B USD
  3. Fiscal year 2018: Dividends paid 2.3B USD · Share repurchases 4.2B USD · New shares issued (including employee plans) not available · Free cash flow 4.3B USD
  4. Fiscal year 2019: Dividends paid 2.4B USD · Share repurchases 4.4B USD · New shares issued (including employee plans) not available · Free cash flow 3.8B USD
  5. Fiscal year 2020: Dividends paid 2.7B USD · Share repurchases 500.0M USD · New shares issued (including employee plans) not available · Free cash flow 5.1B USD
  6. Fiscal year 2021: Dividends paid 3.1B USD · Share repurchases 1.3B USD · New shares issued (including employee plans) not available · Free cash flow 6.0B USD
  7. Fiscal year 2022: Dividends paid 3.5B USD · Share repurchases 1.5B USD · New shares issued (including employee plans) not available · Free cash flow 5.2B USD
  8. Fiscal year 2023: Dividends paid 4.1B USD · Share repurchases 750.0M USD · New shares issued (including employee plans) not available · Free cash flow 792.5M USD
  9. Fiscal year 2024: Dividends paid 4.7B USD · Share repurchases 2.5B USD · New shares issued (including employee plans) not available · Free cash flow 3.8B USD
  10. Fiscal year 2025: Dividends paid 5.4B USD · Share repurchases 4.1B USD · New shares issued (including employee plans) not available · Free cash flow 9.0B USD

Dividends paid, repurchases and new shares issued from the cash flow statement of annual reports filed with the SEC (as first reported). Describes the reported figures – not investment advice.

Valuation over time

Price-based valuation (P/E, P/S, price/free cash flow and dividend yield per fiscal year, compared with its own average) for signed-in users.

Sector comparison

Lilly (Eli) next to 8 stocks of the sector Health Care we cover that are closest in revenue. Click a column header to sort the table.

Sector comparison LLY, sector Health Care; last row: sector median
Symbol Revenue (FY) Growth 5 yrsGross marginOp. marginNet marginROEEquity ratioFCF marginPiotroski
JNJ Johnson & Johnson 94.2B USD +2.7%67.9%–28.5%32.9%40.9%20.9%4/9
HCA HCA Healthcare 75.6B USD +8.0%––9.0%–−9.9%10.2%–
LLY Lilly (Eli) this stock 65.2B USD +21.6%83.0%–31.7%77.8%23.6%13.8%7/9
MRK Merck & Co. 65.0B USD +6.3%74.8%–28.1%34.7%38.4%19.0%4/9
PFE Pfizer 62.6B USD +8.5%74.3%–12.4%9.0%41.5%14.5%6/9
ABBV AbbVie 61.2B USD +6.0%70.2%24.6%6.9%–−2.4%29.1%8/9
BMY Bristol Myers Squibb 48.2B USD +2.5%71.1%–14.6%38.2%20.5%26.7%8/9
TMO Thermo Fisher Scientific 44.6B USD +6.7%–17.4%15.0%12.6%48.4%14.1%–
ABT Abbott Laboratories 44.3B USD +5.1%56.4%18.2%14.7%12.5%60.1%16.7%6/9
Median of the sector 26 symbols 44.4B USD +8.5%66.6%18.0%13.9%14.3%38.5%14.9%7/9

Growth 5 yrs = revenue growth per year over 5 fiscal years · Op. margin = operating margin · ROE = return on equity · FCF = free cash flow · Piotroski = F-Score (only with all 9 criteria).

Figures of the last fiscal year from SEC annual reports (peers as of Oct 28, 2026). Median across all companies of the sector we cover (from 5 stocks; several share classes of one company count once). Signed-in users also see P/E, P/S and dividend yield in the comparison. Describes the reported figures – not investment advice.

Key figures with traffic lights

Each light follows a simple, disclosed rule. The comparison is with the sector median of all 63 symbols in the Health Care sector on our list (current members of the S&P 500 and other lists).

Revenue growth

Light green: above sector

+21.6% per year, last 5 years

Sector Health Care: median +7.8% (60 symbols)

What does this mean? Revenue: over 5 years it grew by 21.6% per year on average – at least as fast as the median company in the sector (+7.8%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net income (total)

Light green: above sector

+27.2% per year, last 5 years

Sector Health Care: median +7.5% (46 symbols)

per share: +27.6% per year (5 years, split-adjusted)

What does this mean? Total net income: over 5 years it grew by 27.2% per year on average – at least as fast as the median company in the sector (+7.5%).

Light rule: Green: grows at least as fast as the sector median (without a sector comparison: grows) · Yellow: grows more slowly · Red: shrinks.

Net margin

Light green: above sector

31.7% last fiscal year

Sector Health Care: median 12.9% (63 symbols)

What does this mean? Of every 100 USD in revenue, 31.67 USD remained as profit – at least as much as the median company in the sector (12.9%). Five years ago the margin was 25.2%.

Light rule: Green: at least the sector median (without a sector comparison: profit) · Yellow: profit, but below the median · Red: loss.

Debt / equity

Light red: much higher

1.41 latest balance sheet

Sector Health Care: median 0.66 (49 symbols)

What does this mean? For every 1 USD of equity there is 1.41 USD of financial debt – more than twice as much as the median company in the sector (0.66). More debt amplifies good and bad years alike.

Light rule: Green: at most the sector median · Yellow: up to twice the median · Red: more than twice · Gray: without a sector comparison.

Payout ratio

Light green: covered

27% Dividend / earnings per share

Sector Health Care: median 28% (31 symbols)

What does this mean? Of every 1 USD of earnings per share, 0.27 USD went to shareholders as a dividend. The rest stays in the company. Median company in the sector: 28%.

Light rule: Green: up to 60% of earnings · Yellow: up to 100% · Red: more than earnings or a dividend despite a loss · Gray for real estate (REITs). The sector median is for comparison only.

Profitable years

Light yellow: 1 loss year

9 of 10 fiscal years with a profit

What does this mean? In 9 of the last 10 fiscal years the bottom line showed a profit. One year ended with a loss.

Light rule: Green: profit in every year · Yellow: one loss year · Red: several loss years (at least 3 years needed).

Last fiscal year and 13F

Information, not a trading signal · Source: SEC EDGAR
Revenue (FY)
65.2B USD
Revenue vs. prior year
+44.7%
Net income (FY)
20.6B USD
Net income vs. prior year
+94.9%
EPS (FY)
22.95 USD
13F funds with a position
3 of 9
Funds vs. prior quarter
+1
Shares held vs. prior quarter
−75.6%
Fiscal year to Dec 31, 2025 · 10-K filed Feb 12, 2026 · Balance sheet Jun 30, 2026 (filed Aug 5, 2026) · Price-based figures (P/E, P/S, dividend yield, market cap) only when logged in. · Values as first reported; debt = reported financial debt (US GAAP: long-term). 13F: reporting date Jun 30, 2026, 9 tracked funds have filed (latest Aug 14, 2026), filed with up to 45 days of delay. Stock positions only; comparison with Mar 31, 2026 only across funds that filed for both quarters.
All figures as a table
Fiscal years (amounts in USD, per share in USD)
YearEndRevenueNet income MarginEarnings per shareDividend per sharePayout
2025Dec 31, 2025 65.2B20.6B 31.7% 22.95 6.23 27%
2024Dec 31, 2024 45.0B10.6B 23.5% 11.71 5.40 46%
2023Dec 31, 2023 34.1B5.2B 15.4% 5.80 4.69 81%
2022Dec 31, 2022 28.5B6.2B 21.9% 6.90 4.07 59%
2021Dec 31, 2021 28.3B5.6B 19.7% 6.12 3.53 58%
2020Dec 31, 2020 24.5B6.2B 25.2% 6.79 3.07 45%
2019Dec 31, 2019 22.3B8.3B 37.3% 8.89 2.68 30%
2018Dec 31, 2018 24.6B3.2B 13.2% 3.13 2.33 74%
2017Dec 31, 2017 22.9B−204.1M −0.9% −0.19 2.12 –
2016Dec 31, 2016 21.2B2.7B 12.9% 2.58 2.05 79%
Quarters (amounts in USD, per share in USD)
QuarterEndRevenueNet income MarginEarnings per shareDividend per sharePayout
Q2/26Jun 30, 2026 23.0B7.1B 30.9% 7.94 3.46 44%
Q1/26Mar 31, 2026 19.8B7.4B 37.4% 8.26 – –
Q4/25*Dec 31, 2025 19.3B6.6B 34.4% – 3.23 –
Q3/25Sep 30, 2025 17.6B5.6B 31.7% 6.21 – –
Q2/25Jun 30, 2025 15.6B5.7B 36.4% 6.29 3.00 48%
Q1/25Mar 31, 2025 12.7B2.8B 21.7% 3.06 – –
Q4/24*Dec 31, 2024 13.5B4.4B 32.6% – 2.80 –
Q3/24Sep 30, 2024 11.4B970.3M 8.5% 1.07 – –
Q2/24Jun 30, 2024 11.3B3.0B 26.3% 3.28 2.60 79%
Q1/24Mar 31, 2024 8.8B2.2B 25.6% 2.48 – –
Q4/23*Dec 31, 2023 9.4B2.2B 23.4% – 2.43 –
Q3/23Sep 30, 2023 9.5B−57.4M −0.6% −0.06 – –

* Q4 derived: fiscal year minus the 9-month value (EPS cannot be derived this way); may be distorted by restatements.

How we calculate: values as first reported to the SEC (later corrections are left out), a fixed order of reporting tags per figure, partial sums are never added up. Growth per year over 5 years (otherwise 3 years). Quarters are labeled by the calendar quarter in which they end.

Insiders

All insider transactions
Insider purchases and sales on the market over 3, 6 and 12 months
PeriodPurchasesSalesNet
3 months $00 people $16.0M3 people −$16.0M
6 months $00 people $34.6M5 people −$34.6M
12 months $00 people $78.4B5 people −$78.4B

Latest transactions

  • Aug 17, 2026 Jonsson Patrik Officer Open-market sale · 10b5-1 plan 6,500 shares · $7.6M · SEC
  • Aug 10, 2026 Zakrowski Donald A Officer Open-market sale · 10b5-1 plan 2,000 shares · $2.4M · SEC
  • Aug 7, 2026 Hakim Anat Officer Open-market sale · 10b5-1 plan 5,000 shares · $6.0M · SEC
  • Jun 10, 2026 Yuffa Ilya Officer Open-market sale · 10b5-1 plan 2,500 shares · $2.9M · SEC
  • May 6, 2026 Lilly Endowment Inc other person Open-market sale 2,208 shares · $2.2M · SEC
  • May 6, 2026 Lilly Endowment Inc other person Open-market sale 13,620 shares · $13.6M · SEC

Source: mandatory filings with the SEC (Form 4), open-market purchases and sales only. General information, not investment advice.

Trend score +80

Price vs. EMA 50+15
Price vs. EMA 200+15
EMA 50 vs. EMA 200+20
ADX (trend strength)+15
Highs and lows+0
Relative strength+15

Volatility and trend strength

ADX 14 (trend strength)32.3
Rel. strength 60 d+13.2%

ATR and moving averages as price values only when logged in.

More stocks from Health Care

All symbols in this sector

News

Latest news

Posts

No posts on LLY yet – log in to join the discussion.

Posts are opinions of users and only visible after logging in. Community rules

Set alert: LLY

Alerts with a free account: we send you an email as soon as the price moves above or below your level.

Checked after every data update: crypto hourly (buy zones every 4 hours), stocks twice a day, precious metals every 4 hours on trading days, extended universe weekly – not in real time.

Log in Sign up free

↑ ↓ select · Enter open · Esc close